Novartis considers eye care division IPO or spin-off
In a relatively quiet week for live equity deals, Novartis, one of Europe’s largest pharmaceutical companies, has said it is considering an IPO or spin-off of its eye care division, and a real estate investment trust announced the year’s first London IPO of significant size.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: